Study identifier:D9831C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, placebo-controlled, randomised, parallel group phase IIa study to evaluate the histological changes, cellularity, clinical efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Phase 2
No
AZD1981, Placebo
All
52
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2013 by AstraZeneca
AstraZeneca
-
The purpose of this study is to study histological changes, cellularity, clinical efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
Location
Location
Frieburg, Germany
Location
GROßHANSDORF, Germany
Location
Hannover, Germany
Location
LEICESTER, United Kingdom
Location
London, United Kingdom
Location
Manchester, United Kingdom
Location
Newcastle upon Tyne, United Kingdom
Location
Amsterdam, Netherlands
Arms | Assigned Interventions |
---|---|
Experimental: AZD1981 | Drug: AZD1981 Oral tablet, twice daily, 4 weeks treatment |
Placebo Comparator: Placebo | Drug: Placebo Placebo |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.